Alembic Pharma gets final approval from USFDA for OCD treatment drug

PTIUpdated: Thursday, August 05, 2021, 01:14 PM IST
article-image
Alembic Pharma has a cumulative total of 149 abbreviated new drug application (ANDA) approvals |

Drug firm Alembic Pharmaceuticals on Thursday said it has received final approval from the US health regulator for Clomipramine Hydrochloride capsules, used for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).

The company has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Clomipramine Hydrochloride Capsules USP in the strengths 25 mg, 50 mg, and 75 mg, Alembic Pharmaceuticals said in a regulatory filing.

The approved product is therapeutically equivalent to the reference-listed drug product Anafranil Capsules of SpecGX LLC.

Clomipramine Hydrochloride Capsules are indicated for the treatment of obsessions and compulsions in patients with OCD.

Quoting IQVIA data, Clomipramine Hydrochloride Capsules USP 25 mg, 50 mg, and 75 mg have an estimated market size of USD 32 million for twelve months ending June 2021.

Alembic has a cumulative total of 149 abbreviated new drug application (ANDA) approvals, which includes 131 final approvals and 18 tentative approvals, from USFDA.

(To receive our E-paper on whatsapp daily, please click here. To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

Rate hike of 50 points on the cards as RBI panel meets on Wednesday

Rate hike of 50 points on the cards as RBI panel meets on Wednesday

Lack of confidence among lenders reportedly halts grounded Jet Airways’ comeback

Lack of confidence among lenders reportedly halts grounded Jet Airways’ comeback

Gurugram-based firm Blade orders 200 electric air taxis to be deployed in five years

Gurugram-based firm Blade orders 200 electric air taxis to be deployed in five years

China will feel isolated, globalization at inflection point: Asia's richest man Gautam Adani

China will feel isolated, globalization at inflection point: Asia's richest man Gautam Adani

Sundar Pichai says fun isn’t all about money, while defending cost cutting at Google

Sundar Pichai says fun isn’t all about money, while defending cost cutting at Google